Axsome Therapeutics’ Auvelity expanded its label to include treating agitation in Alzheimer’s disease patients. It’s just the second FDA-approved drug for this indication, and Axsome’s pill has a safety advantage.
The post Axsome Drug’s FDA Approval Unlocks New Opportunity in Alzheimer’s Agitation appeared first on MedCity News.
